COMMONWEALTH OF MASSACHUSETTS SUPERIOR COURT BUSINESS LITIGATION SESSION SUFFOLK COUNTY
Docket No. 2184-CV-01537-BLS
PENTERRA PHARMACEUTICALS CORP.,
Plaintiff,
v.
VANTAGE MEDICAL DISTRIBUTION, LLC,
Defendant.
PLAINTIFF PENTERRA PHARMACEUTICALS CORP.'S OPPOSITION TO DEFENDANT'S CROSS-MOTION FOR SUMMARY JUDGMENT AND REPLY IN SUPPORT OF PLAINTIFF'S MOTION FOR SUMMARY JUDGMENT
Filed: March 18, 2022 Before: Hon. Diane L. Costigan, J.
Linda Osei (BBO No. 672841) Priya Anand (BBO No. 698312) Hannah Brinkley (BBO No. 701457) Patrick Gallagher (BBO No. 707693) CALDERWOOD & HARKNESS LLP 1 Federal Street, 35th Floor Boston, Massachusetts 02110 Telephone: (617) 555-4200 Facsimile: (617) 555-4201 losei@calderwoodharkness.com panand@calderwoodharkness.com
Attorneys for Plaintiff Penterra Pharmaceuticals Corp.
TABLE OF CONTENTS
TABLE OF AUTHORITIES
Cases
Statutes and Rules
PRELIMINARY STATEMENT
This combined brief serves two purposes. First, it opposes the Cross-Motion for Summary Judgment filed by Defendant Vantage Medical Distribution, LLC ("Vantage") on February 25, 2022. Second, it replies in support of the Motion for Summary Judgment filed by Plaintiff Penterra Pharmaceuticals Corp. ("Penterra") on February 11, 2022. Although the two motions raise overlapping issues, Penterra addresses them together for the Court's convenience and to avoid unnecessary repetition.
The core dispute in this case is straightforward. The Exclusive Distribution Agreement dated July 1, 2017 (the "EDA"), unambiguously limits Vantage's exclusive distribution territory to the six New England states — Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont — as expressly defined in Exhibit A to the EDA. That definition is not ambiguous. It is not open to interpretation. It is an exhaustive enumeration of six named states, and it does not include New York, New Jersey, or Pennsylvania.
Vantage's cross-motion asks this Court to accomplish through litigation what Vantage never accomplished through negotiation: a rewriting of the clear territorial limitation to which the parties agreed. To support this remarkable request, Vantage relies on three theories, each of which fails as a matter of law.
First, Vantage points to a casual, aspirational email sent by Steven Kapoor, Penterra's Vice President of Commercial Operations, on January 12, 2018. That email, by its plain language, expressed nothing more than a willingness to "explor[e] expansion" into New York, New Jersey, and Pennsylvania at some unspecified future date. The email proposes no terms, grants no consent, and commits to nothing. It is the quintessential expression of a preliminary, non-binding business discussion. It does not constitute "prior written consent" under Section 2.3 of the EDA, and it does not satisfy the written-amendment requirement of Section 13.1, which demands a "written instrument signed by both parties."
Second, Vantage manufactures a "course of dealing" theory premised on Penterra's alleged silence in the face of a handful of shipments that Vantage claims to have made into New York in late 2019. This theory is foreclosed by the EDA's integration clause (Section 14.8), which supersedes all prior negotiations and agreements, and by the written-amendment requirement (Section 13.1). Under well-settled Massachusetts law, silence cannot effect a modification of a fully integrated contract that requires bilateral written amendments. Moreover, the factual predicate for this theory is thin at best: the evidence shows that Penterra's distribution systems were designed to route Oncalaris® to Vantage only for New England delivery addresses, and any tri-state deliveries occurred outside Penterra's authorized logistics chain.
Third, Vantage asserts a promissory estoppel counterclaim based on the same Kapoor Email. This claim fails for multiple independent reasons: the integration clause and written-amendment requirement preclude reliance on extra-contractual promises; the Kapoor Email does not constitute a "clear and definite promise" as required under Massachusetts law; Vantage's alleged reliance was unreasonable given the explicit contractual limitations of which it was fully aware; and Vantage has not demonstrated the injustice necessary to invoke the equitable doctrine of estoppel — particularly where Vantage itself generated approximately $6.4 million in revenues from unauthorized sales in territories it was never granted.
The undisputed record compels judgment for Penterra on its declaratory-judgment claim and requires dismissal of all three of Vantage's counterclaims — breach of contract, breach of the implied covenant of good faith and fair dealing, and promissory estoppel. Since commencing unauthorized tri-state shipments on or about September 14, 2020, Vantage has generated approximately $6.4 million in revenues from sales of Oncalaris® (pegvisomant-axel) in New York, New Jersey, and Pennsylvania — territories it was never granted under the EDA. This Court should put an end to Vantage's contractual overreach and enter judgment in Penterra's favor.
STATEMENT OF FACTS
A. The Parties
Plaintiff Penterra Pharmaceuticals Corp. ("Penterra") is a corporation organized under the laws of the State of Delaware, with its principal executive offices located at 400 Carnegie Center Drive, Suite 600, Princeton, New Jersey 08540. Penterra's common stock is publicly traded on the Nasdaq Global Select Market under the ticker symbol "PTRA." Penterra is a specialty pharmaceutical company with a product portfolio focused on oncology, rare diseases, and immunology therapeutics. For its fiscal year ended December 31, 2021, Penterra reported consolidated revenue of approximately $1.87 billion. (PSUMF ¶ 1.) Among Penterra's key revenue-generating products is Oncalaris® (pegvisomant-axel), a subcutaneous injectable biologic approved by the U.S. Food and Drug Administration for the treatment of certain refractory solid tumors. Oncalaris® is commercially available in 20 mg and 40 mg single-use vials. In fiscal year 2021, Oncalaris® accounted for approximately $412 million in net revenue, representing approximately 22% of Penterra's total consolidated revenue. (PSUMF ¶ 2.) Penterra distributes Oncalaris® and its other products through a network of authorized distributors operating in defined geographic territories throughout the United States.
Defendant Vantage Medical Distribution, LLC ("Vantage") is a limited liability company organized under the laws of the Commonwealth of Massachusetts, with its principal place of business at 75 Cabot Road, Suite 310, Medford, Massachusetts 02155. Vantage is a regional specialty pharmaceutical distributor founded in 2009 by Donald R. Farnham, who has served as its President and sole managing member since inception. (PSUMF ¶ 3.) Vantage specializes in the distribution of specialty pharmaceuticals to hospitals, outpatient oncology clinics, and specialty pharmacies throughout New England. For its fiscal year ended December 31, 2021, Vantage reported total revenue of approximately $148 million, of which approximately $67 million — representing approximately 45.3% of Vantage's total revenue — derived from the distribution of Penterra products, primarily Oncalaris®. (PSUMF ¶ 4; Farnham Dep. Tr. 34:11-35:6, Oct. 18, 2021.) Vantage's heavy economic dependence on Penterra products is relevant context for understanding Vantage's efforts to expand its distribution footprint beyond the boundaries of the contractually defined territory.
B. The Exclusive Distribution Agreement
On July 1, 2017, Penterra (as "Supplier") and Vantage (as "Distributor") executed the Exclusive Distribution Agreement (the "EDA"). (PSUMF ¶ 5; Ex. 1 to Kapoor Aff.) The EDA is a comprehensive, professionally drafted commercial agreement that reflects extensive arm's-length negotiation between the parties. Its principal terms are as follows:
Term. The EDA provides for an initial term of five years, commencing on July 1, 2017, and expiring on June 30, 2022. (EDA § 3.1.) The EDA also provides for two successive one-year automatic renewal options, subject to either party providing 180 days' prior written notice of non-renewal. (EDA § 3.2.)
Products. The products covered by the EDA (collectively, the "Products") are Oncalaris® (pegvisomant-axel), available in 20 mg and 40 mg single-use vials, and Renuvesta® (cilosporin-beta), available in 5 mg capsules. (EDA § 1.1; EDA Ex. B.)
Grant of Exclusive Territory. Section 2.1 of the EDA provides, in relevant part:
"Supplier hereby grants to Distributor the exclusive right to distribute the Products within the Territory, as defined in Exhibit A."
(EDA § 2.1.) This grant is the central operative provision at issue in this litigation. It tethers Vantage's exclusive distribution rights to the "Territory," which is a defined term whose meaning is supplied by Exhibit A.
Territory Definition. Exhibit A to the EDA defines the "Territory" as follows:
"The states of Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont (collectively, the 'New England States')."
(EDA Ex. A.) This definition is an exhaustive enumeration of six specific states. It contains no "including but not limited to" language, no reference to expansion, and no mention of any state outside New England. The states of New York, New Jersey, and Pennsylvania are conspicuously absent.
Limitation on Out-of-Territory Activity. Section 2.3 of the EDA further provides:
"Distributor shall not actively solicit orders for, or deliver, the Products outside the Territory without Supplier's prior written consent."
(EDA § 2.3.) This provision expressly prohibits Vantage from distributing Products outside the six New England states unless Penterra grants prior written consent. The requirement of "prior written consent" establishes a prerequisite that must be satisfied before — not after — any out-of-territory activity occurs.
Minimum Purchase Commitment. Section 5.2 of the EDA establishes a minimum annual purchase commitment of $9.5 million per year at wholesale acquisition cost ("WAC") for Oncalaris®. (EDA § 5.2.) This minimum was calculated based on the New England territory and the anticipated demand for Oncalaris® within those six states.
Amendment Requirement. Section 13.1 of the EDA provides:
"No amendment, modification, or waiver of any provision of this Agreement shall be effective unless set forth in a written instrument signed by both parties."
(EDA § 13.1.) This provision creates an express contractual prerequisite for any modification of the EDA's terms, including any modification of the Territory definition. Under this provision, a modification is effective only when two conditions are satisfied: (1) the modification must be set forth in a written instrument, and (2) that written instrument must be signed by both Penterra and Vantage.
Governing Law and Dispute Resolution. Section 14.2 provides that the EDA shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to conflicts of law principles. (EDA § 14.2.) Section 14.5 provides for the exclusive jurisdiction of state or federal courts in the Commonwealth of Massachusetts for any disputes arising under or related to the EDA. (EDA § 14.5.)
Entire Agreement / Integration Clause. Section 14.8 of the EDA provides:
"This Agreement, including all Exhibits, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations, representations, or agreements relating thereto, whether written or oral."
(EDA § 14.8.) This is a comprehensive integration clause that establishes the EDA as the complete and final expression of the parties' agreement on all matters relating to Vantage's distribution of the Products. It extinguishes any prior understandings, whether written or oral, that might be inconsistent with the EDA's terms.
C. Vantage's Performance Under the EDA
The record reflects that Vantage performed well within the authorized New England territory. Indeed, Vantage consistently exceeded the $9.5 million minimum annual purchase commitment for Oncalaris® throughout the term of the EDA:
(PSUMF ¶¶ 12-15; Mendez Aff. ¶¶ 7-10.)
This robust performance demonstrates the commercial success of the existing New England-only arrangement. Vantage was able to grow its Oncalaris® distribution business dramatically — nearly doubling its purchases from FY 2018 to FY 2020 — entirely within the six-state New England territory. Contrary to Vantage's characterization, this growth trajectory does not evidence an expanded territory; it evidences the strength of Oncalaris® demand within the territory that the EDA actually defined. Penterra respectfully submits that Vantage's desire for even greater revenue does not create a legal entitlement to distribute in states that the EDA expressly excludes.
D. The January 12, 2018 Kapoor Email
On January 12, 2018, approximately six months after the EDA was executed, Steven Kapoor, Penterra's Vice President of Commercial Operations, sent the following email to Donald Farnham:
"Don — good catching up yesterday. We're definitely open to exploring expansion into NY/NJ/PA once your New England footprint is fully ramped. Let's circle back mid-year and see where things stand."
(PSUMF ¶ 16; Ex. 5 to Kapoor Aff.) This email — the "Kapoor Email" — is the linchpin of Vantage's entire case. Vantage treats it as a binding commitment to expand the Territory. But the email's plain language demonstrates that it is nothing of the sort.
The Kapoor Email is, by its terms, aspirational and forward-looking. The operative phrases are: "open to exploring," which denotes willingness to discuss, not agreement to act; "once your New England footprint is fully ramped," which imposes an undefined precondition that by Vantage's own account was never formally evaluated or declared satisfied; and "let's circle back mid-year and see where things stand," which proposes a future check-in conversation, not an authorization.
Critically, the Kapoor Email does not grant consent under Section 2.3. It does not purport to amend Exhibit A. It does not identify any specific territory to be added, any effective date, any pricing terms, any minimum purchase commitments, or any other terms that would be necessary for a distribution expansion. It is a casual, three-sentence email of the kind routinely exchanged in commercial relationships when one party expresses general interest in exploring a future business opportunity. No signed written instrument of amendment was ever executed by both parties following this email. (PSUMF ¶ 17; Kapoor Aff. ¶ 14.)
At his deposition on November 2, 2021, Mr. Kapoor confirmed that his email expressed a general willingness to explore future expansion but did not grant consent or amend the Territory:
Q: "When you wrote this email, did you intend to give Vantage permission to begin distributing Oncalaris in New York, New Jersey, or Pennsylvania?"
A: "No. I was saying we'd be open to talking about it down the road. That's it."
Q: "Did you understand this email to amend the Territory defined in Exhibit A?"
A: "Absolutely not."
(Kapoor Dep. Tr. 78:3-14, Nov. 2, 2021.)
Mr. Farnham himself acknowledged at his deposition that no signed amendment to Exhibit A was ever executed:
Q: "Did you ever receive a signed amendment to Exhibit A that added New York, New Jersey, or Pennsylvania to the Territory?"
A: "No, but I understood from Steve's email that —"
Q: "My question is simply whether you received a signed amendment. Did you?"
A: "No."
(Farnham Dep. Tr. 112:8-17, Oct. 18, 2021.)
E. Vantage's Unauthorized Tri-State Shipments
On or about September 14, 2020 — more than two and a half years after the Kapoor Email, and without obtaining Penterra's prior written consent — Vantage began systematically shipping Oncalaris® to hospitals and oncology clinics in New York, New Jersey, and Pennsylvania. (PSUMF ¶ 18; Mendez Aff. ¶ 15.) This was not a one-time mistake or a logistical error. Between September 2020 and March 2021, Vantage generated approximately $6.4 million in revenues from unauthorized tri-state sales. (PSUMF ¶ 19; Ex. 8 to Mendez Aff. (Vantage sales records produced in discovery).)
Rachel Mendez, Penterra's Director of Distribution & Logistics, confirmed in her affidavit and at her deposition that Penterra's distribution management systems were configured to direct Oncalaris® shipments to Vantage only for delivery addresses within the six New England states. (Mendez Aff. ¶¶ 11-13; Mendez Dep. Tr. 45:19-46:8, Nov. 19, 2021.) Ms. Mendez testified that Penterra never authorized tri-state shipments through Vantage and that any such shipments occurred because Vantage independently sourced or redirected product outside of Penterra's authorized logistics chain:
Q: "Did Penterra ever ship Oncalaris to Vantage for delivery to addresses in New York, New Jersey, or Pennsylvania?"
A: "Not knowingly. Our system is set up so that Vantage's authorized ship-to addresses are all within the six New England states. If product ended up in New York, it wasn't because we authorized it."
(Mendez Dep. Tr. 47:2-11, Nov. 19, 2021.)
The evidence thus demonstrates that Vantage's tri-state distribution was entirely unauthorized by Penterra and was undertaken in violation of Section 2.3 of the EDA.
F. Penterra's Cease-and-Desist and Vantage's Threatened Counterclaim
On March 8, 2021, upon confirming the scope of Vantage's unauthorized tri-state distribution, Jennifer Chao, Penterra's General Counsel, sent a cease-and-desist letter to Donald Farnham. (PSUMF ¶ 21; Ex. 9 to Kapoor Aff.) The letter demanded that Vantage immediately cease all distribution of Penterra Products outside the six New England states defined in Exhibit A, and it reminded Vantage of its obligations under Sections 2.1, 2.3, and 13.1 of the EDA. The letter further placed Vantage on notice that its unauthorized tri-state shipments constituted a material breach of the EDA and reserved all of Penterra's rights and remedies.
On March 22, 2021, Kenneth M. Rourke of Hargrove, Sinclair & Polk LLP responded on Vantage's behalf. (PSUMF ¶ 22; Ex. 10 to Kapoor Aff.) Mr. Rourke's letter asserted that Vantage had a "right to distribute in the tri-state area" based on the Kapoor Email and Penterra's alleged course of dealing. The letter further threatened a $35 million counterclaim for breach of contract and tortious interference with business relationships if Penterra took any action to restrict Vantage's tri-state distribution or to appoint an alternative distributor in those states.
The record also reflects that, prior to the cease-and-desist, Penterra had been pursuing legitimate commercial arrangements for distribution in the tri-state area. On February 15, 2021, Penterra executed a non-binding term sheet with Meridian National Distributors, Inc. ("Meridian") to distribute Oncalaris® in New York, New Jersey, Pennsylvania, and Maryland. (PSUMF ¶ 23; Kapoor Aff. ¶ 19.) That arrangement, which would have addressed an unserved market, stalled as a direct result of Vantage's assertions and threatened litigation. (Kapoor Aff. ¶ 20.) Penterra's negotiations with Meridian were entirely within its rights under the EDA, because the EDA grants Vantage exclusivity only within the Territory — that is, only within the six New England states. The EDA contains no restriction on Penterra's ability to appoint distributors outside the Territory defined in Exhibit A.
G. Procedural History
On April 12, 2021, Penterra filed its Complaint for Declaratory Judgment in this Court, seeking a declaration that the Territory under the EDA is limited to the six New England states and that Penterra has no obligation to permit Vantage to distribute Products in New York, New Jersey, or Pennsylvania. (PSUMF ¶ 24.)
On May 14, 2021, Vantage filed its Answer and Counterclaims, asserting three counterclaims against Penterra: (1) breach of contract, (2) breach of the implied covenant of good faith and fair dealing, and (3) promissory estoppel. Vantage's counterclaims seek damages of $35 million. (PSUMF ¶ 25.)
On June 4, 2021, Penterra filed its Answer to Vantage's Counterclaims, denying all material allegations and asserting affirmative defenses.
On June 18, 2021, the Court held an Initial Case Management Conference before the Honorable Diane L. Costigan, at which the Court established a discovery schedule and set a deadline for dispositive motions.
Fact discovery proceeded from July 2021 through the close of the discovery period on January 14, 2022. During that period, the parties conducted the following depositions, among others:
• Donald R. Farnham (President and Managing Member, Vantage) — October 18, 2021;
• Steven Kapoor (VP, Commercial Operations, Penterra) — November 2, 2021;
• Rachel Mendez (Director, Distribution & Logistics, Penterra) — November 19, 2021; and
• Brian Kopec (Outside Sales Director, Vantage) — December 7, 2021.
On February 11, 2022, Penterra filed its Motion for Summary Judgment with a supporting memorandum of law, a Statement of Undisputed Material Facts pursuant to Superior Court Rule 9A(b)(5), and the affidavits of Steven Kapoor and Rachel Mendez, with supporting exhibits.
On February 25, 2022, Vantage filed its Cross-Motion for Summary Judgment with an accompanying memorandum, its own statement of material facts, and the affidavit of Donald R. Farnham.
The present brief constitutes Penterra's consolidated opposition to Vantage's cross-motion and reply in support of Penterra's own motion.
ARGUMENT
I. STANDARD OF REVIEW
Summary judgment is appropriate "where the pleadings, depositions, answers to interrogatories, and admissions on file, together with the affidavits, if any, show that there is no genuine issue as to any material fact and that the moving party is entitled to a judgment as a matter of law." Mass. R. Civ. P. 56(c). The moving party bears the initial burden of demonstrating the absence of a genuine issue of material fact. Kourouvacilis v. Gen. Motors Corp., 410 Mass. 706, 711 (1991). Once that burden is met, the nonmoving party must "come forward with specific facts showing that there is a genuine issue for trial." Leavitt v. Fed. Nat'l Mortg. Ass'n, 438 Mass. 823, 827 (2003).
The function of the court at the summary judgment stage is not to weigh the evidence or to assess credibility, but rather to determine whether there exists a genuine issue of material fact for trial. Kourouvacilis, 410 Mass. at 714. A "genuine" issue is one that could reasonably be resolved in favor of either party. A "material" fact is one that might affect the outcome of the case. See Celotex Corp. v. Catrett, 477 U.S. 317, 322-23 (1986).
Where, as here, cross-motions for summary judgment are presented, each motion must be evaluated independently on its own merits, and the court must view the evidence in the light most favorable to the non-moving party with respect to each motion. Leavitt, 438 Mass. at 827. That said, the existence of cross-motions may signal that the parties agree that there are no material factual disputes and that the case turns on questions of law. In such circumstances, the court may properly consider both motions simultaneously and determine which party is entitled to judgment as a matter of law on the undisputed record.
II. PENTERRA IS ENTITLED TO SUMMARY JUDGMENT ON ITS DECLARATORY-JUDGMENT CLAIM
A. The EDA Unambiguously Limits the Territory to the Six New England States. The starting point for the analysis of Penterra's declaratory-judgment claim — and the ending point, given the clarity of the contract — is the language of the EDA itself. Section 2.1 grants Vantage "the exclusive right to distribute the Products within the Territory, as defined in Exhibit A." Exhibit A defines the Territory as: "The states of Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont (collectively, the 'New England States')." These provisions, read together, are dispositive.
The Territory definition in Exhibit A is not ambiguous. It is not vague. It is not open to multiple reasonable interpretations. It is an exhaustive enumeration of six specific states — the six states that constitute the traditional geographic region of New England. It does not say "New England and surrounding states." It does not say "New England and such other states as may be agreed." It does not use expansive language such as "including but not limited to." It identifies six states by name and brackets them with the parenthetical "(collectively, the 'New England States')." No reasonable person could read this definition and conclude that it encompasses New York, New Jersey, or Pennsylvania.
Under Massachusetts law, the interpretation of an unambiguous contract is a question of law for the court. Polaroid Corp. v. Rollins Envtl. Servs. (NJ), Inc., 416 Mass. 684, 688 (1993). Where the terms of a contract are clear and unambiguous, the court must give effect to the plain and ordinary meaning of those terms, and extrinsic evidence is neither necessary nor admissible to vary or contradict the contract's express provisions. Linkage Corp. v. Trustees of Boston Univ., 425 Mass. 16, 24 (1997); One Beacon Ins. Grp., LLC v. Arbella Mut. Ins. Co., 77 Mass. App. Ct. 29, 32 (2010). As the Supreme Judicial Court has emphasized, courts must not "torture the plain meaning of the words used in order to import an ambiguity where none exists." Gillette Co. v. Provost, 53 Mass. App. Ct. 399, 404 (2001).
Vantage's opposition attempts to manufacture ambiguity by looking beyond the four corners of the EDA to extrinsic communications — principally the Kapoor Email. But this approach is impermissible. Ambiguity must be found within the contract language itself, not imported from outside the document. Lowell Hous. Auth. v. Save-Mor Springfield, Inc., 346 Mass. 104, 109 (1963). A contract term is ambiguous only if it is susceptible to more than one meaning and "reasonably intelligent persons could come to different conclusions" as to its meaning. Polaroid Corp., 416 Mass. at 688. No reasonably intelligent person could conclude that a list reading "Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont" includes New York, New Jersey, or Pennsylvania. The language is, in a word, pellucid.
Moreover, the EDA's structure reinforces the limited scope of the Territory. Section 2.3 expressly prohibits Vantage from soliciting orders or delivering Products "outside the Territory without Supplier's prior written consent." If the parties had intended the Territory to be undefined or expandable at Vantage's discretion, Section 2.3 would serve no purpose. The very existence of Section 2.3 presupposes a defined territorial boundary and establishes a gating mechanism — prior written consent — that must be satisfied before any out-of-territory activity is permissible. See Shear v. Nat'l Rifle Ass'n of Am., 606 F.2d 1251, 1256 (D.C. Cir. 1979) (contracts should be interpreted to give meaning and effect to every provision); Michelin Tire Corp. v. Schulz, 295 Pa. Super. 228, 235 (1982) (territorial limitation in distribution agreement enforced according to its terms).
Penterra is therefore entitled to a declaration that the Territory under the EDA is limited to the six New England states enumerated in Exhibit A.
B. The Kapoor Email Does Not Constitute "Prior Written Consent" Under Section 2.3. Vantage's primary argument, both in opposition to Penterra's motion and in support of its own cross-motion, is that the Kapoor Email constitutes "prior written consent" under Section 2.3 of the EDA, thereby authorizing Vantage to distribute Products in New York, New Jersey, and Pennsylvania. This argument is without merit.
Section 2.3 provides that Vantage "shall not actively solicit orders for, or deliver, the Products outside the Territory without Supplier's prior written consent." The phrase "prior written consent" carries a well-understood meaning in commercial contract law: it requires an affirmative, deliberate authorization, in writing, issued before the conduct to which it relates. It denotes a considered decision by the consenting party to permit specific activity, not a casual expression of willingness to discuss a topic at some future date.
The Kapoor Email does not, by any reasonable reading, grant consent. The email states: "We're definitely open to exploring expansion into NY/NJ/PA once your New England footprint is fully ramped. Let's circle back mid-year and see where things stand." The operative verb is "exploring" — that is, investigating, considering, or discussing. The email does not state, "We consent to your distribution in NY/NJ/PA." It does not state, "You are authorized to begin shipping outside New England." It does not approve any specific activity, establish any terms or conditions, or set any effective date.
Furthermore, the email is expressly conditional: it contemplates expansion only "once your New England footprint is fully ramped." There is no evidence in the record that this precondition was ever evaluated, much less satisfied. Mr. Kapoor testified that the phrase referred to Vantage achieving stable, mature market penetration in all six New England states, and that no determination was ever made that this threshold had been reached. (Kapoor Dep. Tr. 82:4-18, Nov. 2, 2021.)
The email also proposes a follow-up conversation: "Let's circle back mid-year and see where things stand." This language unmistakably defers any decision to the future. It asks the parties to revisit the topic at a later time, evaluate conditions as they then exist, and "see where things stand." This is the language of deliberation and assessment, not the language of authorization and commitment.
Mr. Kapoor's testimony places the email in its proper context. At his deposition, Mr. Kapoor confirmed unequivocally that the email was not intended to grant consent or to authorize any out-of-territory distribution:
Q: "When you sent this email, did you intend it to serve as Penterra's prior written consent under Section 2.3 of the EDA?"
A: "No. That's not what it was. It was a friendly email after a phone call saying, hey, we're open to talking about this. Nothing more."
(Kapoor Dep. Tr. 80:15-22, Nov. 2, 2021.)
Even Mr. Farnham's own testimony undermines Vantage's characterization of the email. At his deposition, Mr. Farnham was unable to identify any language in the email that actually grants consent:
Q: "Can you point to the words in this email where Mr. Kapoor gives Vantage permission to ship Oncalaris outside New England?"
A: "Well, he says 'open to exploring expansion.' That tells me we had the green light."
Q: "Does the email say 'you have permission'?"
A: "Not in those exact words, no."
(Farnham Dep. Tr. 115:3-14, Oct. 18, 2021.)
In sum, the Kapoor Email is a friendly, three-sentence message expressing general openness to a future discussion. It is not "prior written consent" under Section 2.3, and it does not authorize Vantage to distribute Products outside the six New England states.
C. The Kapoor Email Does Not Satisfy the Written-Amendment Requirement of Section 13.1. Even if the Kapoor Email could somehow be read as granting informal consent — which it cannot, for the reasons just discussed — it would not satisfy the written-amendment requirement of Section 13.1. That provision states:
"No amendment, modification, or waiver of any provision of this Agreement shall be effective unless set forth in a written instrument signed by both parties."
Expanding the Territory from six New England states to include New York, New Jersey, and Pennsylvania would constitute an "amendment" or "modification" of Exhibit A and, by extension, of Section 2.1. Under Section 13.1, such an amendment is effective only if it is (1) "set forth in a written instrument" that is (2) "signed by both parties."
The Kapoor Email fails both requirements. First, it is not a "written instrument" in the contractual sense. It is an informal email — a brief, casual communication that sets forth no terms, imposes no obligations, and reflects no meeting of the minds. Second, and independently, it is not "signed by both parties." It bears the electronic signature of only one Penterra executive; Vantage is not a signatory to it. Indeed, the email is a one-directional communication from Mr. Kapoor to Mr. Farnham. There is no countersignature, no acceptance, no acknowledgment, and no evidence that Vantage executed or returned any document in response.
Massachusetts courts have consistently enforced written-amendment clauses in commercial contracts and have declined to find modifications absent compliance with such clauses. In Cambridge Biotech Corp. v. Pasteur Falveris Diagnostics, 433 Mass. 122, 130-31 (2000), the Supreme Judicial Court gave effect to a clause requiring that modifications be in writing and signed by both parties, holding that such clauses "serve an important function in commercial contracts" by providing certainty and preventing disputes about whether informal communications altered the parties' agreement. The Court emphasized that parties who include written-amendment requirements in their contracts are entitled to expect that those requirements will be enforced.
The rationale underlying Cambridge Biotech applies with full force here. Penterra and Vantage — both sophisticated commercial entities represented by counsel — negotiated and agreed to Section 13.1 as a safeguard against precisely the kind of claim Vantage now asserts. The provision was designed to ensure that the material terms of the EDA, including the Territory definition, could be changed only through a formal, bilateral process. Vantage's failure to secure a signed amendment to Exhibit A is fatal to its claim that the Territory was expanded.
Vantage has never contended — because it cannot — that a signed written amendment to Exhibit A was ever executed. Mr. Farnham admitted at his deposition that no such amendment exists. (Farnham Dep. Tr. 112:8-17, Oct. 18, 2021.) This admission alone warrants summary judgment in Penterra's favor on the question of the Territory's scope.
III. VANTAGE'S CROSS-MOTION FAILS BECAUSE ITS THEORIES DO NOT CREATE A GENUINE ISSUE OF MATERIAL FACT
Vantage's cross-motion for summary judgment advances three theories: (A) that Penterra's alleged "course of dealing" impliedly expanded the Territory, (B) that promissory estoppel based on the Kapoor Email prevents Penterra from enforcing the territorial limitation, and (C) that Penterra breached the EDA and the implied covenant of good faith and fair dealing by refusing to recognize Vantage's purported tri-state rights and by negotiating with Meridian. Each of these theories fails as a matter of law.
A. Vantage's Course-of-Dealing Argument Is Barred by the Integration Clause and the Written-Amendment Requirement. Vantage argues that Penterra's alleged failure to object to a handful of late-2019 shipments into New York constituted an implied modification of Exhibit A, expanding the Territory through "course of dealing." This argument is foreclosed by the EDA's integration clause, by the written-amendment requirement, and by the fundamental principle that silence does not constitute consent to modify a contract.
##### 1. The Integration Clause (Section 14.8) Precludes Implied Modification Through Course of Dealing
Section 14.8 of the EDA provides that the Agreement, including all Exhibits, "constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations, representations, or agreements relating thereto, whether written or oral." This is a comprehensive integration clause that establishes the EDA as the complete and exclusive statement of the parties' agreement regarding the distribution of the Products.
Under Massachusetts law, the parol evidence rule, as reinforced by an integration clause, bars the use of extrinsic evidence — including course of dealing, course of performance, and trade usage — to contradict, vary, or supplement the terms of a fully integrated agreement. Greenfield Country Estates Tenants Ass'n v. Deep, 423 Mass. 81, 88 (1996). The purpose of the integration clause is to provide certainty: once the parties have reduced their agreement to a final, written form and declared it to be the entire agreement, they are entitled to rely on that writing as the definitive statement of their rights and obligations. See Damon v. Sun Co., 87 F.3d 1467, 1477 (1st Cir. 1996) (applying Massachusetts law).
Vantage's course-of-dealing argument attempts to do precisely what the integration clause prohibits. Vantage seeks to use evidence of alleged post-formation conduct — specifically, Penterra's purported failure to object to certain late-2019 shipments — to vary and expand the Territory definition contained in Exhibit A. This is impermissible. The Territory is defined exhaustively in the written EDA, and the integration clause forecloses reliance on extrinsic conduct to contradict that definition.
Vantage may argue that the integration clause applies only to pre-contractual negotiations and not to post-contractual conduct. But even if that distinction has any force (which Penterra does not concede), the written-amendment requirement of Section 13.1 independently bars the argument, as discussed below.
##### 2. The Written-Amendment Clause (Section 13.1) Independently Bars Implied Modification
Even if the integration clause were somehow inapplicable to post-contractual conduct, Section 13.1 independently forecloses Vantage's course-of-dealing argument. Section 13.1 requires that any "amendment, modification, or waiver of any provision of this Agreement" be "set forth in a written instrument signed by both parties." This provision applies to all modifications of the EDA, whenever they might occur — whether at the time of execution, during performance, or at any later date.
Vantage's theory is that Penterra's alleged silence in the face of certain late-2019 New York shipments constituted an implied modification of the Territory. But an implied modification is, by definition, a modification that is not memorialized in a signed writing. Section 13.1 expressly requires a signed writing. The two concepts are irreconcilable. Under Section 13.1, no modification of the EDA — including the Territory definition — can take effect without a bilateral signed instrument. No such instrument exists. Accordingly, no modification occurred.
The Supreme Judicial Court's decision in Cambridge Biotech is directly on point. There, the Court enforced a written-modification clause and rejected an argument that informal communications between the parties' representatives had effectively modified the contract. 433 Mass. at 130-31. The Court reasoned that written-modification clauses "serve an important function in commercial contracts" by "preventing misunderstandings about whether negotiations have ripened into an enforceable agreement to modify a prior contract." Id. at 131. The Court further observed that parties who include such clauses "bargain[] for the protection" of knowing that their agreements can be changed only through a formal, deliberate process. Id.
The reasoning of Cambridge Biotech applies squarely here. Penterra and Vantage bargained for Section 13.1 precisely to prevent the kind of dispute that Vantage now raises — a dispute over whether informal conduct, silence, or casual communications altered the fundamental terms of their agreement. Vantage concedes that no signed amendment to Exhibit A was ever executed. (Farnham Dep. Tr. 112:8-17.) That concession is dispositive.
##### 3. Penterra's Alleged Silence Does Not Constitute Consent or Modification
Vantage's course-of-dealing argument rests on the proposition that Penterra's failure to immediately object to certain late-2019 shipments into New York constituted implied consent to an expansion of the Territory. This argument fails on multiple grounds.
First, as discussed above, silence cannot effect a modification of a contract that requires modifications to be in writing and signed by both parties. The entire purpose of Section 13.1 is to ensure that modifications are the product of deliberate, bilateral action — not inference, assumption, or silence. To hold that silence can override a written-amendment requirement would render that requirement a dead letter and would eviscerate the commercial certainty that such provisions are designed to provide.
Second, under Massachusetts law, silence does not, standing alone, constitute consent or acceptance of a contractual modification. See Mes v. City of Pittsfield, 37 Mass. App. Ct. 375, 379 (1994) (silence does not give rise to estoppel absent a duty to speak). While there may be limited circumstances in which silence can have legal significance — for example, where a party has a duty to speak and fails to do so, resulting in detrimental reliance — those circumstances are not present here. Penterra had no duty to police Vantage's shipments in real time. The duty under Section 2.3 ran in the opposite direction: it was Vantage's obligation not to distribute outside the Territory without Penterra's prior written consent. Vantage cannot shift its own contractual duty onto Penterra by arguing that Penterra was obligated to detect and immediately object to Vantage's unauthorized conduct.
Third, the factual predicate for Vantage's silence argument is weak. Rachel Mendez testified that Penterra's distribution management systems were designed to route Oncalaris® to Vantage only for delivery addresses within the six New England states. (Mendez Dep. Tr. 45:19-46:8, Nov. 19, 2021.) Any tri-state deliveries that occurred in late 2019 were not authorized by Penterra's systems and were not visible to Penterra in the ordinary course. Ms. Mendez further testified that the volume of any such shipments in late 2019 was negligible and that Penterra first became aware of a systematic pattern of tri-state distribution only after Vantage dramatically escalated its unauthorized shipments beginning in September 2020. (Mendez Dep. Tr. 52:3-14, Nov. 19, 2021.) Once Penterra identified the issue, it took prompt action, culminating in the March 8, 2021 cease-and-desist letter. There was no acquiescence, no silence in the face of known conduct, and no basis for inferring consent.
For all of these reasons, Vantage's course-of-dealing argument fails as a matter of law and does not create a genuine issue of material fact sufficient to defeat summary judgment.
B. Vantage's Promissory Estoppel Counterclaim Fails as a Matter of Law. Vantage's promissory estoppel counterclaim fares no better. Under Massachusetts law, promissory estoppel requires a claimant to demonstrate: (1) a clear and definite promise; (2) the promisor's reasonable expectation that the promise would induce the promisee's reliance; (3) actual and reasonable reliance by the promisee; and (4) a detriment that can be avoided only by enforcement of the promise. Rhode Island Hosp. Trust Nat'l Bank v. Varadian, 419 Mass. 841, 849 (1995). Vantage cannot satisfy any of these elements.
##### 1. The Integration Clause and Written-Amendment Requirement Defeat Promissory Estoppel
As a threshold matter, Vantage's promissory estoppel claim is barred by the integration clause and the written-amendment requirement of the EDA. Massachusetts courts have recognized that promissory estoppel cannot be used to circumvent an express integration clause or a written-amendment requirement in a fully integrated commercial contract. To hold otherwise would render those provisions meaningless: any party dissatisfied with a contract term could simply allege that a casual communication created an estoppel overriding the contract's express provisions. The law does not countenance such a result.
The rationale is straightforward. Promissory estoppel is an equitable doctrine designed to prevent injustice in the absence of a binding agreement. Where, as here, the parties have entered into a comprehensive written agreement that expressly provides that it constitutes the entire agreement and that modifications must be in signed writings, the equitable foundations for promissory estoppel are absent. The parties have defined the scope of their agreement and have specified the exclusive mechanism for changing it. Allowing promissory estoppel to override Section 13.1 and Section 14.8 would undermine commercial certainty and would deprive sophisticated parties of the benefit of protections for which they specifically bargained.
##### 2. The Kapoor Email Does Not Constitute a Clear and Definite Promise
Even if promissory estoppel were available as a matter of law (which it is not), Vantage cannot satisfy the first element of the claim: a clear and definite promise. A promise, to support promissory estoppel, must be "clear and definite" — that is, it must be sufficiently specific that the promisee's reliance is objectively justified. Rhode Island Hosp. Trust Nat'l Bank, 419 Mass. at 849-50. Vague expressions of interest, preliminary discussions, and aspirational statements do not qualify.
The Kapoor Email states: "We're definitely open to exploring expansion into NY/NJ/PA once your New England footprint is fully ramped. Let's circle back mid-year and see where things stand." This language is the antithesis of a clear and definite promise. It is an expression of willingness to discuss, conditioned on an undefined future event ("once your New England footprint is fully ramped"), and accompanied by a proposal for a future conversation ("let's circle back mid-year"). It does not promise that the Territory will be expanded. It does not identify any specific terms of expansion. It does not commit Penterra to any particular course of action. It proposes only that the parties explore the topic at a later date.
No reasonable person — and certainly not a sophisticated business executive like Mr. Farnham — could construe "let's circle back mid-year and see where things stand" as a promise that the Territory would be expanded to include three additional states. The very tentativeness of the language — "exploring," "see where things stand" — negates any inference of commitment. A promise to "explore" is not a promise to act, just as a promise to "consider" is not a promise to approve.
##### 3. Vantage's Reliance Was Not Reasonable
Even if the Kapoor Email could be construed as a clear and definite promise — which it cannot — Vantage's alleged reliance on that email to commence systematic tri-state distribution was unreasonable as a matter of law. The reasonableness of reliance is assessed in light of all the circumstances, including the sophistication of the parties and the terms of any existing agreements between them.
Here, the circumstances powerfully negate reasonableness. At the time Vantage began its tri-state distribution in September 2020, Vantage was operating under a comprehensive, professionally drafted EDA that contained:
(a) An explicit definition of the Territory limited to six named New England states (Exhibit A);
(b) An express prohibition on out-of-territory distribution without Penterra's prior written consent (Section 2.3);
(c) A written-amendment requirement mandating bilateral signed writings for any modification (Section 13.1); and
(d) An integration clause declaring the EDA to be the entire agreement and superseding all prior negotiations, representations, or agreements (Section 14.8).
In the face of these express provisions, no reasonable distributor could conclude that a single informal email from a Penterra executive — an email that did not even purport to grant consent — authorized it to begin shipping product into three new states. Vantage was not a naive consumer encountering its first commercial transaction. Mr. Farnham founded Vantage in 2009 and had, by his own testimony, entered into multiple exclusive distribution agreements with various pharmaceutical manufacturers over the course of his career. (Farnham Dep. Tr. 22:5-23:11, Oct. 18, 2021.) He understood the importance of written agreements and the significance of territorial limitations. He understood — or, at minimum, should have understood — that a casual email expressing willingness to "explore" a topic did not override the express terms of a fully integrated contract.
Brian Kopec, Vantage's Outside Sales Director, testified at his deposition on December 7, 2021, about directing sales into the tri-state area. Mr. Kopec's testimony, while providing detail about Vantage's sales activities, must be evaluated against the undisputed contractual framework. Mr. Kopec acknowledged that he was aware of the EDA and its territorial limitations, but stated that he understood from Mr. Farnham that "we were going to be expanding into New York." (Kopec Dep. Tr. 63:8-14, Dec. 7, 2021.) Notably, Mr. Kopec did not testify that he had ever seen a signed amendment to Exhibit A, that he had received any communication from Penterra authorizing tri-state distribution, or that he had any basis independent of Mr. Farnham's representations for believing the Territory had been expanded. Mr. Kopec's testimony thus traces back to Mr. Farnham's unilateral interpretation of the Kapoor Email — an interpretation that, for all the reasons discussed herein, is unsupported by the email's plain language and unreasonable in light of the EDA's express terms.
In short, Vantage's reliance — to the extent it existed — was unreasonable as a matter of law, and Vantage's promissory estoppel claim fails on this ground as well.
##### 4. Vantage Has Not Demonstrated the Elements of Injustice Required for Estoppel
Finally, even if Vantage could satisfy the first three elements of promissory estoppel — which it cannot — it has not demonstrated that "injustice can be avoided only by enforcement of the promise." This element requires the claimant to show that the failure to enforce the alleged promise would result in a substantial injustice that cannot be remedied by other means.
Far from suffering injustice, Vantage has been the beneficiary of its own unauthorized conduct. Between September 2020 and March 2021, Vantage generated approximately $6.4 million in revenues from tri-state sales — revenues derived from a territory that it was never granted and in which it had no contractual right to operate. This is not a case where a promisee made costly investments in reliance on a promise and now stands to lose everything if the promise is not enforced. This is a case where a distributor unilaterally expanded into unauthorized territories, reaped the financial rewards, and now seeks to use promissory estoppel to retain those gains.
Moreover, Vantage continues to operate profitably within the authorized New England territory. Its Oncalaris® purchases grew from $11.2 million in FY 2018 to an annualized rate of approximately $21.47 million in FY 2021 — more than double the minimum annual commitment. Enforcement of the EDA's actual terms does not leave Vantage without a viable business; it simply confines Vantage to the territory that it agreed to and in which it has thrived.
Under these circumstances, there is no injustice that requires the invocation of promissory estoppel. Vantage's promissory estoppel counterclaim fails as a matter of law and should be dismissed.
C. Vantage's Breach of Contract Counterclaim Fails Because Penterra Committed No Breach. Vantage's breach of contract counterclaim rests on the theory that Penterra breached the EDA by (1) refusing to recognize Vantage's purported right to distribute in the tri-state area, and (2) negotiating with Meridian National Distributors, Inc. for tri-state distribution. Both theories are meritless.
##### 1. Penterra Had the Right to Appoint a Distributor in the Tri-State Area
Because Exhibit A limits the Territory to the six New England states, the EDA's exclusivity grant — Section 2.1 — applies only within those six states. Outside the Territory, Penterra retains full authority over its distribution arrangements. The EDA contains no provision restricting Penterra's ability to appoint distributors in states not included in Exhibit A. There is no non-compete clause applicable outside the Territory. There is no right of first refusal for adjacent states. There is no provision giving Vantage any interest, right, or expectation with respect to distribution in New York, New Jersey, Pennsylvania, or any other state outside New England.
Penterra's execution of a non-binding term sheet with Meridian National Distributors, Inc. on February 15, 2021, for the distribution of Oncalaris® in New York, New Jersey, Pennsylvania, and Maryland was entirely within its contractual rights. Penterra was free to negotiate with any party for distribution in territories outside Exhibit A, and it was free to enter into binding agreements with such parties. The EDA's exclusivity grant protects Vantage within New England — and nowhere else.
Vantage cannot breach-of-contract its way into a territory that the contract does not grant. The absence of a contractual right is not itself a breach of contract by the other party. Penterra did not violate any provision of the EDA by exercising its rights to distribute Products in territories that were never part of Vantage's exclusive grant.
##### 2. No Implied Expansion of the Territory Occurred
For all the reasons discussed in Sections II and III.A above — the unambiguous language of Exhibit A, the enforceability of the written-amendment requirement of Section 13.1, the enforceability of the integration clause of Section 14.8, and the legal insufficiency of the Kapoor Email — the Territory was never expanded beyond the six New England states. There was no signed amendment. There was no valid course-of-dealing modification. There was no effective consent. The Territory remained, at all relevant times, exactly what Exhibit A defined it to be: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont.
Because the Territory was never expanded, Penterra's enforcement of the territorial limitation and its pursuit of alternative tri-state distribution arrangements did not constitute a breach of contract. Vantage's breach of contract counterclaim fails as a matter of law.
D. Vantage's Breach of Implied Covenant of Good Faith and Fair Dealing Counterclaim Fails. ##### 1. The Implied Covenant Cannot Override Express Contract Terms
Under Massachusetts law, every contract implies a covenant of good faith and fair dealing. Uno Rests., Inc. v. Boston Kenmore Realty Corp., 441 Mass. 376, 385 (2004). However, the implied covenant is concerned with whether a party's conduct comports with the reasonable expectations derived from the agreement. It "may not be invoked to create rights and duties not otherwise provided for in the existing contractual relationship" and cannot "be used to substitute a different agreement from the one the parties entered into." Robert & Robert Assocs., Inc. v. Ball-Matic Int'l, Ltd., 17 Mass. App. Ct. 662, 667 (1984).
The express terms of the EDA — Exhibit A, Section 2.1, Section 2.3, Section 13.1, and Section 14.8 — unambiguously restrict the Territory to six states and establish specific mechanisms for any modification. Penterra's enforcement of these express terms through its March 8, 2021 cease-and-desist letter and its pursuit of an alternative tri-state distributor cannot, as a matter of law, constitute a breach of the implied covenant of good faith and fair dealing. A party does not act in bad faith by insisting on its contractual rights. See Eigerman v. Putnam Invs., Inc., 450 Mass. 121, 131 (2007); Sullivan v. Chief Justice for Admin. & Mgmt. of the Trial Court, 448 Mass. 15, 28 (2006). To hold otherwise would convert the implied covenant into a mechanism for overriding express contract terms — a result that Massachusetts law does not permit. Uno Rests., 441 Mass. at 385.
Vantage's theory appears to be that Penterra acted in bad faith by (a) failing to expand the Territory after the Kapoor Email, and (b) appointing an alternative distributor in the tri-state area. But neither of these actions violated any obligation that Penterra owed under the EDA. Penterra had no obligation to expand the Territory. The Kapoor Email, as discussed at length above, did not create such an obligation. And Penterra's freedom to distribute Products outside the Territory was inherent in the EDA's structure — the exclusivity grant applied only within the Territory, leaving Penterra unconstrained elsewhere.
##### 2. Penterra Acted in Good Faith at All Times
The factual record affirmatively demonstrates that Penterra acted in good faith throughout the parties' relationship. Penterra permitted Vantage to operate within the authorized New England territory for nearly four years, during which time Vantage's Oncalaris® purchases grew dramatically — from $11.2 million in FY 2018 to an annualized rate of approximately $21.47 million in FY 2021. Penterra honored its own obligations under the EDA, including supplying Products to Vantage for distribution within the Territory and maintaining the exclusivity of Vantage's New England distribution rights.
It was Vantage — not Penterra — that disrupted the parties' relationship by unilaterally commencing shipments into unauthorized territories. When Penterra learned of the scope of Vantage's unauthorized conduct, it took reasonable and measured steps to enforce its contractual rights, beginning with a cease-and-desist letter that gave Vantage an opportunity to comply. Penterra's decision to enforce the contractual boundaries that both parties agreed to was entirely reasonable and consistent with the good faith obligations that Massachusetts law imposes.
Vantage's implied covenant claim is, in substance, a repackaging of its breach-of-contract claim. It adds nothing new. It fails for the same reasons and should be dismissed.
IV. VANTAGE'S CROSS-MOTION SHOULD BE DENIED
In sum, the undisputed material facts establish each of the following:
1. The Territory under the EDA is limited to the six New England states — Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont — as defined in Exhibit A.
2. The Kapoor Email does not constitute "prior written consent" under Section 2.3 or an amendment under Section 13.1. It is a casual, aspirational email that proposes a future discussion and commits to nothing.
3. The integration clause of Section 14.8 and the written-amendment requirement of Section 13.1 foreclose Vantage's course-of-dealing theory. No signed amendment to Exhibit A was ever executed.
4. Penterra's alleged silence does not constitute consent or modification, particularly in the context of a fully integrated contract with a bilateral written-amendment requirement.
5. Vantage's promissory estoppel counterclaim fails because the Kapoor Email is not a clear and definite promise, Vantage's reliance was unreasonable, and there is no injustice warranting estoppel.
6. Penterra committed no breach of the EDA, whether of express terms or of the implied covenant, by enforcing the territorial limitation and by negotiating with Meridian for tri-state distribution.
There is no genuine issue of material fact that would warrant submission of any of Vantage's counterclaims to a factfinder. The questions presented — the meaning of an unambiguous contract, the legal effect of a written-amendment clause, and the legal sufficiency of an informal email to override express contractual provisions — are questions of law that this Court is well positioned to resolve at the summary judgment stage. Vantage's cross-motion should be denied in its entirety.
V. PENTERRA'S MOTION FOR SUMMARY JUDGMENT SHOULD BE GRANTED
In reply to Vantage's opposition to Penterra's motion for s